Skip to main content
Erschienen in: Breast Cancer Research 5/2011

01.10.2011 | Viewpoint

The amplifier effect: how Pin1 empowers mutant p53

verfasst von: Hai Hu, Gerburg M Wulf

Erschienen in: Breast Cancer Research | Ausgabe 5/2011

Einloggen, um Zugang zu erhalten

Abstract

Mutation of p53 occurs in 15 to 20% of all breast cancers, and with higher frequency in estrogen-receptor negative and high-grade tumors. Certain p53 mutations contribute to malignant transformation not only through loss of wild-type p53 but also through a gain of function of specific p53 mutations. How these hotspot mutations turn p53 from a tumor suppressor into an oncogene had until now remained incompletely understood. In an elegant paper published in the July 12 issue of Cancer Cell, Girardini and colleagues show how Pin1-mediated prolylisomerization, a regulatory mechanism intended by evolution to support p53's function as a guardian of the genome, can go haywire and accelerate malignant transformation when p53 carries a dominant-negative mutation.
Literatur
1.
Zurück zum Zitat Baker SJ, Markowitz S, Fearon ER, Willson JK, Vogelstein B: Suppression of human colorectal carcinoma cell growth by wild-type p53. Science. 1990, 249: 912-915. 10.1126/science.2144057.CrossRefPubMed Baker SJ, Markowitz S, Fearon ER, Willson JK, Vogelstein B: Suppression of human colorectal carcinoma cell growth by wild-type p53. Science. 1990, 249: 912-915. 10.1126/science.2144057.CrossRefPubMed
2.
Zurück zum Zitat Li FP, Fraumeni JF: Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome?. Ann Intern Med. 1969, 71: 747-752.CrossRefPubMed Li FP, Fraumeni JF: Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome?. Ann Intern Med. 1969, 71: 747-752.CrossRefPubMed
3.
Zurück zum Zitat Olivier M, Langerød A, Carrieri P, Bergh J, Klaar S, Eyfjord J, Theillet C, Rodriguez C, Lidereau R, Bièche I, Varley J, Bignon Y, Uhrhammer N, Winqvist R, Jukkola-Vuorinen A, Niederacher D, Kato S, Ishioka C, Hainaut P, Børresen- Dale AL: The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res. 2006, 12: 1157-1167. 10.1158/1078-0432.CCR-05-1029.CrossRefPubMed Olivier M, Langerød A, Carrieri P, Bergh J, Klaar S, Eyfjord J, Theillet C, Rodriguez C, Lidereau R, Bièche I, Varley J, Bignon Y, Uhrhammer N, Winqvist R, Jukkola-Vuorinen A, Niederacher D, Kato S, Ishioka C, Hainaut P, Børresen- Dale AL: The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res. 2006, 12: 1157-1167. 10.1158/1078-0432.CCR-05-1029.CrossRefPubMed
5.
Zurück zum Zitat Girardini JE, Napoli M, Piazza S, Rustighi A, Marotta C, Radaelli E, Capaci V, Jordan L, Quinlan P, Thompson A, Mano M, Rosato A, Crook T, Scanziani E, Means AR, Lozano G, Schneider C, Del Sal G: A Pin1/mutant p53 axis promotes aggressiveness in breast cancer. Cancer Cell. 2011, 20: 79-91. 10.1016/j.ccr.2011.06.004.CrossRefPubMed Girardini JE, Napoli M, Piazza S, Rustighi A, Marotta C, Radaelli E, Capaci V, Jordan L, Quinlan P, Thompson A, Mano M, Rosato A, Crook T, Scanziani E, Means AR, Lozano G, Schneider C, Del Sal G: A Pin1/mutant p53 axis promotes aggressiveness in breast cancer. Cancer Cell. 2011, 20: 79-91. 10.1016/j.ccr.2011.06.004.CrossRefPubMed
6.
Zurück zum Zitat Lee TH, Pastorino L, Lu KP: Peptidyl-prolyl cis-trans isomerase Pin1 in ageing, cancer and Alzheimer disease. Expert Rev Mol Med. 2011, 13: e21-CrossRefPubMed Lee TH, Pastorino L, Lu KP: Peptidyl-prolyl cis-trans isomerase Pin1 in ageing, cancer and Alzheimer disease. Expert Rev Mol Med. 2011, 13: e21-CrossRefPubMed
7.
Zurück zum Zitat Lu PJ, Zhou XZ, Shen M, Lu KP: Function of WW domains as phosphoserineor phosphothreonine-binding modules. Science. 1999, 283: 1325-1328. 10.1126/science.283.5406.1325.CrossRefPubMed Lu PJ, Zhou XZ, Shen M, Lu KP: Function of WW domains as phosphoserineor phosphothreonine-binding modules. Science. 1999, 283: 1325-1328. 10.1126/science.283.5406.1325.CrossRefPubMed
8.
Zurück zum Zitat Wulf G, Finn G, Suizu F, Lu KP: Phosphorylation-specific prolyl isomerization: is there an underlying theme?. Nat Cell Biol. 2005, 7: 435-441. 10.1038/ncb0505-435.CrossRefPubMed Wulf G, Finn G, Suizu F, Lu KP: Phosphorylation-specific prolyl isomerization: is there an underlying theme?. Nat Cell Biol. 2005, 7: 435-441. 10.1038/ncb0505-435.CrossRefPubMed
9.
Zurück zum Zitat Wulf GM, Ryo A, Wulf GG, Lee SW, Niu T, Petkova V, Lu KP: Pin1 is overexpressed in breast cancer and cooperates with Ras signaling in increasing the transcriptional activity of c-Jun towards cyclin D1. EMBO J. 2001, 20: 3459-3472. 10.1093/emboj/20.13.3459.CrossRefPubMedPubMedCentral Wulf GM, Ryo A, Wulf GG, Lee SW, Niu T, Petkova V, Lu KP: Pin1 is overexpressed in breast cancer and cooperates with Ras signaling in increasing the transcriptional activity of c-Jun towards cyclin D1. EMBO J. 2001, 20: 3459-3472. 10.1093/emboj/20.13.3459.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Wulf GM, Liou YC, Ryo A, Lee SW, Lu KP: Role of Pin1 in the regulation of p53 stability and p21 transactivation, and cell cycle checkpoints in response to DNA damage. J Biol Chem. 2002, 277: 47976-47979. 10.1074/jbc.C200538200.CrossRefPubMed Wulf GM, Liou YC, Ryo A, Lee SW, Lu KP: Role of Pin1 in the regulation of p53 stability and p21 transactivation, and cell cycle checkpoints in response to DNA damage. J Biol Chem. 2002, 277: 47976-47979. 10.1074/jbc.C200538200.CrossRefPubMed
11.
Zurück zum Zitat Zacchi P, Gostissa M, Uchida T, Salvagno C, Avolio F, Volinia S, Ronai Z, Blandino G, Schneider C, Del Sal G: The prolyl isomerase Pin1 reveals a mechanism to control p53 functions after genotoxic insults. Nature. 2002, 419: 853-857. 10.1038/nature01120.CrossRefPubMed Zacchi P, Gostissa M, Uchida T, Salvagno C, Avolio F, Volinia S, Ronai Z, Blandino G, Schneider C, Del Sal G: The prolyl isomerase Pin1 reveals a mechanism to control p53 functions after genotoxic insults. Nature. 2002, 419: 853-857. 10.1038/nature01120.CrossRefPubMed
12.
Zurück zum Zitat Zheng H, You H, Zhou XZ, Murray SA, Uchida T, Wulf G, Gu L, Tang X, Lu KP, Xiao ZX: The prolyl isomerase Pin1 is a regulator of p53 in genotoxic response. Nature. 2002, 419: 849-853. 10.1038/nature01116.CrossRefPubMed Zheng H, You H, Zhou XZ, Murray SA, Uchida T, Wulf G, Gu L, Tang X, Lu KP, Xiao ZX: The prolyl isomerase Pin1 is a regulator of p53 in genotoxic response. Nature. 2002, 419: 849-853. 10.1038/nature01116.CrossRefPubMed
13.
Zurück zum Zitat Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM, Valentin-Vega YA, Terzian T, Caldwell LC, Strong LC, El-Naggar AK, Lozano G: Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell. 2004, 119: 861-872. 10.1016/j.cell.2004.11.006.CrossRefPubMed Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM, Valentin-Vega YA, Terzian T, Caldwell LC, Strong LC, El-Naggar AK, Lozano G: Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell. 2004, 119: 861-872. 10.1016/j.cell.2004.11.006.CrossRefPubMed
14.
Zurück zum Zitat Ryo A, Nakamura M, Wulf G, Liou YC, Lu KP: Pin1 regulates turnover and subcellular localization of beta-catenin by inhibiting its interaction with APC. Nat Cell Biol. 2001, 3: 793-801. 10.1038/ncb0901-793.CrossRefPubMed Ryo A, Nakamura M, Wulf G, Liou YC, Lu KP: Pin1 regulates turnover and subcellular localization of beta-catenin by inhibiting its interaction with APC. Nat Cell Biol. 2001, 3: 793-801. 10.1038/ncb0901-793.CrossRefPubMed
15.
Zurück zum Zitat Lam PB, Burga LN, Wu BP, Hofstatter EW, Lu KP, Wulf GM: Prolyl isomerase Pin1 is highly expressed in Her2-positive breast cancer and regulates erbB2 protein stability. Mol Cancer. 2008, 7: 91-10.1186/1476-4598-7-91.CrossRefPubMedPubMedCentral Lam PB, Burga LN, Wu BP, Hofstatter EW, Lu KP, Wulf GM: Prolyl isomerase Pin1 is highly expressed in Her2-positive breast cancer and regulates erbB2 protein stability. Mol Cancer. 2008, 7: 91-10.1186/1476-4598-7-91.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Finn G, Lu KP: Phosphorylation-specific prolyl isomerase Pin1 as a new diagnostic and therapeutic target for cancer. Curr Cancer Drug Targets. 2008, 8: 223-229. 10.2174/156800908784293622.CrossRefPubMed Finn G, Lu KP: Phosphorylation-specific prolyl isomerase Pin1 as a new diagnostic and therapeutic target for cancer. Curr Cancer Drug Targets. 2008, 8: 223-229. 10.2174/156800908784293622.CrossRefPubMed
Metadaten
Titel
The amplifier effect: how Pin1 empowers mutant p53
verfasst von
Hai Hu
Gerburg M Wulf
Publikationsdatum
01.10.2011
Verlag
BioMed Central
Erschienen in
Breast Cancer Research / Ausgabe 5/2011
Elektronische ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr2941

Weitere Artikel der Ausgabe 5/2011

Breast Cancer Research 5/2011 Zur Ausgabe

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

28.05.2024 NSCLC Nachrichten

Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.